Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Verapamil
  • Vinblastine

abstract

  • The advantage of dexverapamil as an MDR reversal agent is its potential for achieving desired blood levels with substantially less toxicity than the racemic mixture of verapamil. Based on tolerability, it is a suitable drug for further study in clinical trials of malignancies other than RCC that attempt to achieve MDR reversal. The dose of 120 mg/m2 given orally every 6 hours, with dose escalation based on individual tolerance, represents a feasible schedule to be considered for such studies.

publication date

  • January 1995

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 7636536

Additional Document Info

start page

  • 1958

end page

  • 65

volume

  • 13

number

  • 8